Find Faculty
Home>Find Faculty>Mohammad Saleem Bhat, PhD

Mohammad Saleem Bhat, PhD

Mohammed Saleem Bhat
Vice Chair of Research, Department of Surgery
Professor, Department of Surgery, Division of Urology, Rush Medical College
Education

BS, biology/chemistry, Kashmir University, Jammu & Kashmir, India
PG Diploma, environment and health, Annamalai University, Tamil Nadu, India
Masters, toxicology, Jamia Hamdard University, Delhi, India
PhD, toxicology - specialization in cancer prevention, Jamia Hamdard University, Delhi, India
Postdoctoral Fellow, cancer biology, International Agency for Research in Cancer, Lyon, France
Research Associate, cancer prevention, University of Wisconsin - Madison
Assistant Scientist/Research Assistant Professor, University of Wisconsin - Madison

Research Areas

Laboratory research focus: Molecular pathology of prostate cancer, discovery of targeted-drugs and immunotherapies with clinical potential

Personal research focus: Developing novel ethnicity-based discriminatory biopsy and serum-biomarkers, race-based 2D and 3D-organoid models, race-based patient derived xenograft (PDX) models of cancer and transgenic genetically engineered mouse (GEM) models mimicking human cancer

Contact Info:

1735 W. Harrison Street
Cohn Research Building Suite 414
Chicago, IL, 60612
(312) 942-9292
mohammad_saleem_bhat@rush.edu
Links:
Biography

Mohammad Saleem Bhat, PhD, joins Rush University as Vice-Chair of Research in the Department of Surgery from the University of Minnesota. Saleem comes with 25 years of research experience in the field of molecular oncology, cancer therapy and cancer disparity. He has earned his PhD degree in Toxicology and Cancer prevention, and obtained his post-doctoral research training from the International Agency for Cancer Research (World Health Organization), Lyon, France and the University of Wisconsin - Madison. He held staff and faculty positions at the University of Wisconsin (2005-2009), and University of Minnesota (2010-2020). Using cutting-edge molecular biology technologies such as gene-editing, alternative intelligence, genetic-engineered and patient-derived models, his group is engaged in developing (A) non-invasive biomarkers and (B) targeted chemo-immunotherapies for treating prostate cancer. He is actively engaged in developed programs focused on studying the genetic and molecular causes underlying the disparity in African American cancer patients. 

Saleem has authored more than 65 original peer-reviewed articles in leading journals such as PNAS, Cell-reports, JBC, Oncogene, Cancer Research, etc. He is involved in teaching and has mentored more than 25 scientists, undergraduate scholars, and PhD scholars.

Honors and Activities

Honors

  • Research Fellowship, Council for Scientific and Industrial Research
  • Research Fellowship, Department of Ocean Development (India)
  • IARC-Post doctoral Fellowship, World Health Organization (WHO, IARC)
  • Global Programs and Strategy Alliance Award, University of Minnesota

Member of editorial board of scientific journals:

  • 2016-2018 Heliyon
  • 2021-current Cancers
  • 2012-current PLOS-one
  • 2014-current Am. J of Stem Cells
  • 2014-current Am. J of Experimental Urology

Memberships in scientific societies:

  • American Association for Cancer Research, 1995 - present
  • Society of Basic Urologic Research, 2010 - present
  • American Urology Association, 2012 - present

Scientific reviewer of scientific journals:

  • J Biol Chem
  • Oncogene
  • Cancer Res
  • Clin Cancer Res
  • Carcinogenesis
  • Mol Carcinogenesis
  • Molecular Cancer Therapeutics
  • Int J Cancer
  • Neoplasia
  • PLOS one
  • Cancer Lett
  • Mol. Cell Biochem
  • J Pharm Pharmacol
  • Biochemical Pharmacol
  • Food Chem Toxicol
Publications

View complete list of publications for Mohammad Saleem Bhat

Grants
Grants
  • NIH/NCI, R01CA193739 (PI)
    Novel targeted chemo/immunotherapy approach for localized and metastatic CaP
  • NIH/NCI, R01-CA225973 (Co-Investigator; PI: Y. Deng)
    Targeting eIF4A1-dependent HK2 translation axis for prevention of resistant prostate cancer
  • Idea development, W81XWH-08-1-0605 (PI)
    Funding Agency : Department of Defense
    The role of polycomb group gene Bmi-1 in the development of prostate cancer
  • NIH/NCI R21- CA184685-01A1 (PI)
    Novel gene that determines metastatic CaP phenotype in African American men
  • NIH/NCI R21 CA184685-02S1 (PI)
    Goal: Establishing novel cell models of African American prostate cancer
  • NIH/NIMHD U54MD008620 (PI: Konety/Vickers)
    Pilot Grant from parent
    Distinguishing marker in African American prostate cancer patients
  • NIH/NCI R21CA133807 (PI)
    Delaying the hormone refractory prostate cancer by a dietary triterpene Lupeol
  • NIH/NCI R03-CA130064 (PI)
    Lupeol, A Novel Fruit and Vegetable Based Triterpene for Prostate Cancer
  • AICR# 09A074 (PI)
    Funding Agency : American Institute for Cancer Research
    Targeting cFLIP by lupeol, triterpene, for chemoprevention of pancreatic cancer
  • Funding Agency: Masonic Cancer Center, Pilot TWG-Grant (PI)
    MD2 regulates immunosuppressive environment in prostate cancer
  • Funding Agency: Hormel Institute, Paint the Town Pink (PTP) Pilot Award
    Relevance of polycomb family in triple negative breast cancer
Patents
  • 2013 U.S. Patent for anticancer agent Lupeol (Patent #US8618082 B2)
  • 2020 U.S. Provisional Patent application for “Novel S100A4 inhibitor for prostate cancer treatment” (Pending approval)
Invited Presentations
  • Novel therapy for neuroendocrine prostate cancer. Annual AUA/SBUR Conference (American Urology Association / Society of Basic Urology Research), San Francisco, 2018
  • S100A4 a novel biomarker for PCa. Annual Prostate Cancer Symposium, Clark-Atlanta University, Atlanta, 2016
  • Targeting of androgen receptor for prostate cancer. AACR, Philadelphia, USA, 2015
  • Identifying novel androgen receptor transport system. Annual Symposium of Prostate Cancer, Atlanta-Clark University, Atlanta, 2013
  • A novel androgen receptor regulator in prostate cancer. Annual Conference of American Association for Cancer Research, Washington DC, 2011
  • A novel chemopreventive strategy for prostate cancer. Minnesota Chemoprevention Consortium (MC2), meeting, Hormel Foods Corporation, Austin, MN
  • Developing a novel immunotherapy for prostate cancer. Invited talk (virtual) at Hormel Institute, Austin, MN
  • Targeting for PCa treatment. Invited talk at University of Oklahoma Health Sciences Center
  • A Novel transporter of androgen receptor. Mayo Clinic, Rochester, Minnesota
  • Molecular mechanism of S100A4”. Department of Molecular Biology Biochemistry, University of Maryland, Baltimore
  • Chemopreventive approach for prostate cancer. Department of Toxicology, University of Louisville, Kentucky
  • Calcium binding S100 protein family in human health. Central for Translational Research & Cancer, University of West Virginia
  • Novel therapeutic agents for prostate cancer. School of Pharmacy, University of Illinois, Chicago
  • Chemopreventive strategy for prostate cancer. Department of Urology, Chicago University
  • Targeted therapy for prostate cancer. School of Medicine, University of South Carolina
  • Identifying WNT signaling regulator in prostate cancer. Department of Biotechnology & Biochemistry, University of North Carolina
  • Role of S100A4 in prostate cancer development. Department of Carcinogenesis, MD-Anderson Cancer Center, Texas
  • MMP9 and NFB regulating pathway in prostate cancer cells. School of Medicine, Wayne State University, Detroit
  • S100A4 mediated inflammation during tumorigenesis. School of Medicine, University of Massachusetts, Boston, USA, 2008
  • Targeting stem cell pathways for cancer therapy. School of Veterinary Medicine, University of Wisconsin, USA, 2008
Follow Mohammad Saleem Bhat on Twitter